Literature DB >> 14506013

In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

Alicia Gomez-Lopez1, Guillermo Garcia-Effron, Emilia Mellado, Araceli Monzon, Juan L Rodriguez-Tudela, Manuel Cuenca-Estrella.   

Abstract

The aim of the present study was to identify retrospectively trends in the species distributions and the susceptibility patterns of Aspergillus species causing fungal infections in Spanish medical centers from 2000 to 2002. The susceptibilities of 338 isolates to amphotericin B, itraconazole, and voriconazole were tested. Aspergillus fumigatus was the most common species (54.7%), followed by Aspergillus terreus (14.8%) and Aspergillus flavus (13.9%). Non-A. fumigatus species were encountered in 45.3% of the samples studied. The majority of Aspergillus isolates were obtained from respiratory tract specimens, followed by ear and skin samples. The geometric mean (GM) MIC of amphotericin B was 0.56 micro g/ml, and the amphotericin B MIC was >2 micro g/ml for 16 isolates (4.7%). Nine of them were A. terreus. The GM MIC of itraconazole was 0.37, and the itraconazole MIC was >4 micro g/ml for 12 (3.5%) isolates. The voriconazole MICs were also high for 8 of the 12 strains for which itraconazole MICs were high (voriconazole MIC range, 2 to 8 micro g/ml).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506013      PMCID: PMC201144          DOI: 10.1128/AAC.47.10.3085-3088.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Uncommon opportunistic fungi: new nosocomial threats.

Authors:  A H Groll; T J Walsh
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

2.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

Review 3.  Overview: non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts.

Authors:  T J Walsh; A H Groll
Journal:  Curr Opin Investig Drugs       Date:  2001-10

4.  Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi.

Authors:  A Aberkane; M Cuenca-Estrella; A Gomez-Lopez; E Petrikkou; E Mellado; A Monzón; J L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

5.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

6.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

7.  Aspergillus Fumigatus antigen detection in sera from patients at risk for invasive aspergillosis.

Authors:  B F Chumpitazi; C Pinel; B Lebeau; P Ambroise-Thomas; R Grillot
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

8.  Azole cross-resistance in Aspergillus fumigatus.

Authors:  J Mosquera; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

9.  Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus.

Authors:  K Seo; H Akiyoshi; Y Ohnishi
Journal:  Microbiol Immunol       Date:  1999       Impact factor: 1.955

10.  In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae.

Authors:  Cornelia Lass-Flörl; M Nagl; E Gunsilius; C Speth; H Ulmer; R Würzner
Journal:  Mycoses       Date:  2002-06       Impact factor: 4.377

View more
  24 in total

1.  Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.

Authors:  Paul Bowyer; Juan Mosquera; Michael Anderson; Mike Birch; Michael Bromley; David W Denning
Journal:  FEMS Microbiol Lett       Date:  2012-05-21       Impact factor: 2.742

2.  Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

3.  Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus.

Authors:  G Garcia-Effron; E Mellado; A Gomez-Lopez; L Alcazar-Fuoli; M Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

4.  Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility.

Authors:  Laura Alcazar-Fuoli; Emilia Mellado; Guillermo Garcia-Effron; Maria J Buitrago; Jordi F Lopez; Joan O Grimalt; J Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Guillermo Garcia-Effron; Laura Alcazar-Fuoli; Emilia Mellado; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of Aspergillus terreus sensu stricto.

Authors:  Mariana S Fernández; Florencia D Rojas; María E Cattana; María de Los Ángeles Sosa; Cristina A Iovannitti; Cornelia Lass-Flörl; Gustavo E Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

7.  Cryptic species and azole resistance in the Aspergillus niger complex.

Authors:  Susan J Howard; Elizabeth Harrison; Paul Bowyer; Janos Varga; David W Denning
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

8.  In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

9.  In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi.

Authors:  Sarah S Gonçalves; Alberto M Stchigel; Josep Cano; Josep Guarro; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.